Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OKYO
STRONG SELLOKYO Pharma Limited · Healthcare · United Kingdom · $81M · Avg Vol: $235K/d
6
StockRankGet insider-trade alerts
Q
28
V
25
M
22
P/E (TTM)
—
ROE
-263.8%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+7.9%
SMA 50SMA 200
Close
$1.64
RSI (14)
44.2
52W High
$3.35
From 52W High
0.5%
SCORE BREAKDOWN
Quality
28
ROIC
-68.6%10.2
ROE
-263.8%25.0
GP/Assets
-31.9%3.0
Op. Margin
0.0%41.3
FCF/Assets
-28.3%12.4
Piotroski
239.0
Int. Cover
-17.9x19.2
D/E Ratio
0.00x97.8
Current Ratio
2.43x45.8
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-7.1x25.0
P/FCF
—N/A
P/B
-17.4x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
22
52W High %
49%25.0
RS 6M
-34%27.0
SMA 50/200
0.84x28.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-175%2.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$81M
P/E (Forward)
-2.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OKYO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OKYO | OKYO Pharma Limited(you) | $81M | 6 | STRONG SELL |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $70M | 9 | STRONG SELL |
| MREO | Mereo BioPharma Group plc | $50M | 6 | STRONG SELL |
| TLSA | Tiziana Life Sciences Ltd | $114M | 1 | STRONG SELL |
| 4BB.L | 4basebio PLC | $110M | 11 | STRONG SELL |
| IMM.L | ImmuPharma plc | $31M | 2 | STRONG SELL |
| POLB.L | Poolbeg Pharma PLC | $63M | 24 | SELL |
| APTA.L | Aptamer Group PLC | $25M | 4 | STRONG SELL |
| BCYC | Bicycle Therapeutics plc | $270M | 8 | STRONG SELL |
| SBTX.L | SkinBioTherapeutics plc | $42M | 19 | STRONG SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.3%